Diagnosis and Individualized Management of von Willebrand Disease: Expert Perspectives on Synthesizing and Contextualizing the EvidencePremiere Date: Monday, January 24, 2022
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Tuesday, January 24, 2023
Note: Credit Is No Longer Available
|Robert F. Sidonio, Jr, MD, MSc (Moderator)
Associate Professor of Pediatrics, Division of Hematology/Oncology
Associate Director of Hemostasis and Thrombosis
Aflac Cancer and Blood Disorders Center
Children’s Healthcare of Atlanta/Emory University School of Medicine
|Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Division of Hematology
University of Texas Health Science Center
McGovern Medical School
|Jonathan Roberts, MD
Assistant Professor of Pediatrics
Bleeding and Clotting Disorders Institute
University of Illinois College of Medicine at Peoria
Von Willebrand disease (VWD), the most common inherited bleeding disorder, is caused by a deficiency in or dysfunction of von Willebrand factor (VWF),and results in disrupted hemostasis. VWD affects approximately 1% of individuals and can cause a myriad of symptoms, ranging from mucocutaneous bleeding in patients who are mildly affected to gastrointestinal bleeding and joint arthropathy in patients with severe disease. Despite its relatively high prevalence, early diagnosis and effective treatment of VWD have been challenging due to a need for education that contextualizes recently published, multidisciplinary guidelines and provides strategies for incorporating them into practice, including showcasing the role of prophylaxis in patients with severe VWD to prevent significant bleeding and arthropathy.
At the end of this CE activity, participants should be able to:
- Accurately diagnose VWD based on clinical assessments and laboratory tests.
- Individualize the management of VWD.
- Evaluate the evidence for long-term prophylaxis in patients with VWD.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Hematologists, primary care physicians, PAs, nurse practitioners, nurses and pharmacists
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Sidonio reports the following financial relationships:
Grants: Genentech, Inc; Octapharma; and Takeda Pharmaceuticals U.S.A., Inc.
Research Support: Octapharma and Takeda Pharmaceuticals U.S.A., Inc.
Consultant: Band Therapeutics; Bayer; BioMarin; Genentech, Inc.; Guardian Therapeutics; Hema Biologics; LFB; Novo Nordisk; Octapharma; Pfizer Inc.; Roche; Sanofi; Spark Therapeutics, Inc; Takeda Pharmaceuticals U.S.A., Inc; and uniQure.
Dr. Escobar reports the following financial relationships:
Grants: National Hemophilia Foundation (NHF)
Research Support: Bayer; CSL Behring; Genentech, Inc.; Novo Nordisk; Octapharma USA, Inc.; Pfizer Inc.; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.; and uniQure
Consultant: Bayer; BioMarin; CSL Behring; Genentech, Inc./Roche; Kedrion, LFB/Hema Biologics; National Hemophilia Foundation (NHF); Novo Nordisk; Pfizer Inc.; Sanofi; and Takeda Pharmaceuticals U.S.A., Inc.
Dr. Roberts reports the following financial relationships:
Consultant: Genentech, Inc.; Novo Nordisk A/S; Octapharma AG; Pfizer Inc.; Sanofi; Takeda Pharmaceutical Company; and uniQure N.V.
Grants: Takeda Pharmaceutical Company
Speakers Bureau: Novo Nordisk A/S; Octapharma AG; Sanofi Genzyme; and Takeda Pharmaceutical Company
Michael Franks, APRN, AGACNP-BC, FNP-BC (peer reviewer) has no disclosures to report.
Kathleen Blake, PhD (planning committee) has no disclosures to report.
Kellie Busby, PharmD (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).